CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) said it will present at the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026, placing the company before investors at a pivotal moment in its growth.
The appearance comes as Madrigal transitions from a development-stage biotech into a commercial-stage player following recent regulatory milestones for its lead therapy. Investor interest in the company has intensified as attention across the healthcare sector turns to liver disease treatments with near-term revenue potential.
Madrigal is focused on metabolic dysfunction-associated steatohepatitis, or MASH, a serious liver disease affecting millions of patients and long marked by limited treatment options. Its drug Rezdiffra, also known as resmetirom, is a once-daily oral therapy designed to address key biological drivers of the disease.
Rezdiffra is currently the first and only medication approved by both the U.S. Food and Drug Administration and the European Commission for the treatment of MASH in patients with moderate to advanced liver fibrosis. The company is also running a late-stage outcomes trial evaluating the drug in patients with compensated MASH cirrhosis, a population with even higher unmet need.
Participation in the JPMorgan conference places Madrigal alongside major pharmaceutical and biotechnology companies vying for capital and partnerships. For investors, the presentation offers a window into how the company plans to scale commercialization and expand the clinical reach of its flagship therapy as competition in the MASH space accelerates.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.